Uncovering the Gaps: Study Sheds Light on Racial Disparities in IPF Outcomes
December 3rd 2024In part 2 of our interview, Cesar Davila-Chapa, MD, discusses key findings, limitations, and future research directions from his study on racial disparities in idiopathic pulmonary fibrosis (IPF) outcomes.
Read More
Tuberculosis Through Time: Historic Burden, Modern Challenges
October 28th 2024Global respiratory leaders at the CHEST 2024 annual meeting underscored the ongoing clinical burden of tuberculosis, emphasizing that it remains a significant global health challenge that requires ongoing attention and awareness.
Read More
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Early Intervention, Targeted Strategies Needed to Improve Disparities, Survival in Patients With IPF
October 17th 2024Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).
Read More
CHEST 2024 Posters Reveal Disparities in Acute Coronary Syndrome Care, Outcomes
October 16th 2024Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring the urgent need for targeted interventions to address these inequities.
Read More
Dr Cesar Davila-Chapa Calls for Awareness of Racial Differences in IPF Hospitalization
October 16th 2024At CHEST 2024, Cesar Davila-Chapa, MD, University of Nebraska Medical Center, brings awareness to the racial disparities demonstrated in his investigation of idiopathic pulmonary fibrosis (IPF) hospitalizations and outcomes.
Read More
Ineligibility, Limitations to PR Uptake in Patients With AECOPD
October 15th 2024Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.
Read More
Racial, Ethnic Disparities Persist in the Treatment, Hospitalization of Patients With IPF
October 15th 2024Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.
Read More
Impact of Air Pollution on Lung Health Sparks Call for Physician-Led Action at CHEST 2024
October 14th 2024Posters presented at the CHEST 2024 annual meeting demonstrated air pollution's role in lung impairment and disease, highlighting the urgent need for providers to address the escalating impacts of climate change on lung health.
Read More
Dr Maxine Dexter: Physician Voices Are Crucial to Public Health
October 14th 2024During CHEST 2024, Maxine Dexter, MD, Kaiser Permanente, discussed her belief in the vital role of physicians in public health advocacy, drawing from her legislative work on issues as a former Oregon State Representative.
Read More
Dr Daniel Howell Details the Current Types of Therapies for Effective COPD Management
October 9th 2024Chronic obstructive pulmonary disease (COPD) presents a significant challenge for both patients and health care providers and discussions of effective management strategies took center stage at CHEST 2024 in Boston.
Read More
Mepolizumab Reduces Exacerbations in Patients With Severe Asthma, Concurrent COPD, Posters Find
October 8th 2024Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in patients with severe asthma and asthma with concurrent chronic obstructive pulmonary disease (COPD).
Read More
Global Respiratory Leaders Call for Collaboration, Advocacy to Tackle Key Health Challenges
October 8th 2024At the CHEST 2024 annual meeting, international respiratory society leaders highlighted the need for global collaboration to address issues like air pollution and health equity in respiratory care.
Read More
Lung Cancer Experts Encourage Use of System-Based Interventions to Address Racial Disparities
October 7th 2024Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, recommending system-based interventions to improve care equity for patients of color.
Read More
Experts Highlight AI's Potential to Enhance ILD Diagnostic Accuracy Amid Limitations
October 7th 2024Experts at the CHEST 2024 annual meeting agreed that artificial intelligence (AI) should not be relied upon entirely, but instead be used as a tool by radiologists to make a diagnosis of interstitial lung disease (ILD).
Read More
Dr Scott Manaker Looks to the Future of Physician Compensation at CHEST 2024
October 7th 2024One of the first sessions to kick off CHEST 2024 in Boston looked at the future of physician compensation, which highlighted the consolidation of physician practices, unionization, the role of coding and fee-for-service payment, and the impacts of facility reimbursement, inflation, and market conditions.
Read More
Air Pollution Increases IPF Exacerbations, but Role in Disease Progression Remains Uncertain
October 6th 2024Although air pollution is linked to increased exacerbations in patients with idiopathic pulmonary fibrosis (IPF), its role in disease progression remains uncertain, with evidence suggesting that both genetic susceptibility and environmental factors contribute to IPF development.
Read More
AI, Digital Technologies Set to Revolutionize COPD Care, Expert Says
October 6th 2024Caroline Quill, MD, of the University of Rochester Medical Center, highlighted the potential of artificial intelligence (AI) and digital technologies to enhance treatment for chronic obstructive pulmonary disease (COPD) at the CHEST 2024 annual meeting in Boston, Massachusetts.
Read More
The Spectrum of Pulmonary Disease: Dr Parth Rali Highlights CHEST 2024 Agenda
October 3rd 2024Parth Rali, MD, Temple University Hospital, is looking forward to approaching pulmonary vascular diseases as a spectrum, especially when assessing pulmonary embolism and pulmonary hypertension, at CHEST 2024.
Read More